WO2011112689A3 - Salts of an indazolylpyrrolotriazine - Google Patents

Salts of an indazolylpyrrolotriazine Download PDF

Info

Publication number
WO2011112689A3
WO2011112689A3 PCT/US2011/027706 US2011027706W WO2011112689A3 WO 2011112689 A3 WO2011112689 A3 WO 2011112689A3 US 2011027706 W US2011027706 W US 2011027706W WO 2011112689 A3 WO2011112689 A3 WO 2011112689A3
Authority
WO
WIPO (PCT)
Prior art keywords
indazolylpyrrolotriazine
salts
ameliorating
treating
preventing
Prior art date
Application number
PCT/US2011/027706
Other languages
French (fr)
Other versions
WO2011112689A9 (en
WO2011112689A2 (en
Inventor
Shripad S. Bhagwat
Timothy David Gross
Patrick B. O'donnel
Traci L. Savall
Original Assignee
Ambit Biosciences Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Biosciences Corp. filed Critical Ambit Biosciences Corp.
Publication of WO2011112689A2 publication Critical patent/WO2011112689A2/en
Publication of WO2011112689A3 publication Critical patent/WO2011112689A3/en
Publication of WO2011112689A9 publication Critical patent/WO2011112689A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are salts of an indazolylpyrrolotriazine, processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating a proliferative disease.
PCT/US2011/027706 2010-03-11 2011-03-09 Saltz of an indazolylpyrrolotriazine WO2011112689A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31303810P 2010-03-11 2010-03-11
US61/313,038 2010-03-11

Publications (3)

Publication Number Publication Date
WO2011112689A2 WO2011112689A2 (en) 2011-09-15
WO2011112689A3 true WO2011112689A3 (en) 2011-11-03
WO2011112689A9 WO2011112689A9 (en) 2011-12-22

Family

ID=43919890

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/027706 WO2011112689A2 (en) 2010-03-11 2011-03-09 Saltz of an indazolylpyrrolotriazine

Country Status (3)

Country Link
AR (1) AR080504A1 (en)
TW (1) TW201136935A (en)
WO (1) WO2011112689A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142931A1 (en) * 2002-12-13 2004-07-22 Vite Gregory D. C-6 modified indazolylpyrrolotriazines
US20060014741A1 (en) * 2003-12-12 2006-01-19 Dimarco John D Synthetic process, and crystalline forms of a pyrrolotriazine compound

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
ES8702440A1 (en) 1984-10-04 1986-12-16 Monsanto Co Prolonged release of biologically active somatotropins.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (en) 1990-04-17 1994-11-18 Eurand Int METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5958458A (en) 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
ATE268591T1 (en) 1995-06-27 2004-06-15 Takeda Chemical Industries Ltd METHOD FOR PRODUCING DELAYED RELEASE PREPARATIONS
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (en) 1995-09-18 1999-06-23 株式会社資生堂 Delayed release microsphere of drug
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
BR9711585A (en) 1996-10-01 2000-01-18 Cima Labs Inc Composition of microcapsule, with masked flavor, of a water-soluble medicine, pharmaceutical formulation to administer a medicine, and process to disguise the flavor of a medicine.
US6375987B1 (en) 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DE19648576C2 (en) 1996-11-23 1999-08-12 Lohmann Therapie Syst Lts Lozenge for modified release of active substances in the gastrointestinal tract
ATE233088T1 (en) 1996-12-20 2003-03-15 Takeda Chemical Industries Ltd METHOD FOR PREPARING A DELAYED RELEASE COMPOSITION
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (en) 1998-05-16 1999-12-06 허영섭 Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof
US7169410B1 (en) 1998-05-19 2007-01-30 Sdg, Inc. Targeted liposomal drug delivery system
DK1126826T6 (en) 1998-11-02 2019-06-24 Alkermes Pharma Ireland Ltd Multiparticulate modified release of methylphenidate
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6623756B1 (en) 2000-04-27 2003-09-23 Noveon Ip Holdings Corp. Directly compressed solid dosage articles
EP1313473A2 (en) 2000-08-30 2003-05-28 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
DE20220604U1 (en) 2001-07-27 2004-02-26 Yamanouchi Pharmaceutical Co., Ltd. Composition containing fine long-term release particles for tablets that disintegrate quickly in the oral cavity
EP1429742B1 (en) 2001-09-28 2011-05-04 McNeil-PPC, Inc. Modified release dosage forms
CA2435729C (en) 2001-12-19 2005-12-13 Astrazeneca Ab New film coating
US6958161B2 (en) 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
US7485322B2 (en) 2002-12-24 2009-02-03 Lek Pharmaceuticals D.D. Modified release pharmaceutical composition
US7102001B2 (en) 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
US7427414B2 (en) 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142931A1 (en) * 2002-12-13 2004-07-22 Vite Gregory D. C-6 modified indazolylpyrrolotriazines
US20060014741A1 (en) * 2003-12-12 2006-01-19 Dimarco John D Synthetic process, and crystalline forms of a pyrrolotriazine compound

Also Published As

Publication number Publication date
TW201136935A (en) 2011-11-01
AR080504A1 (en) 2012-04-11
WO2011112689A9 (en) 2011-12-22
WO2011112689A2 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
IL225597A0 (en) Pharmaceutical composition, methods for treating and uses thereof
CA2865011C (en) Methods and compositions for treating huntington's disease
WO2012083017A3 (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2011130615A3 (en) Preparation of lacosamide
PL2672966T3 (en) Pharmaceutical composition, methods for treating and uses thereof
AP2012006135A0 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof.
BR112014010206A2 (en) compound, pharmaceutical composition, use of compound, and method for the prophylaxis or treatment of a disease state or condition
RS61827B1 (en) Pharmaceutical composition, methods for treating and uses thereof
ZA201300100B (en) Indolizine derivatives,process for the preparation thereof and therapeutic use thereof
WO2010117738A3 (en) Solid state forms of sitagliptin salts
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
WO2012103810A1 (en) Certain chemical entities, compositions, and methods
WO2012158672A3 (en) Compounds for use in treatment of mucositis
EP2497467A4 (en) Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
EP2786982A4 (en) Amino-propylene-glycol derivatives, preparation method and pharmaceutical composition and use thereof
WO2011073981A3 (en) Betahistine in compositions and methods for treating somnolence
WO2010148314A3 (en) Preparation of esomeprazole and its pharmaceutically acceptable salts
WO2012116254A3 (en) Chrysophaentin analogs that inhibit ftsz protein
WO2011107921A3 (en) Modified release composition of milnacipran
WO2014053962A3 (en) Compositions and methods for treatment of diabetes and pre-diabetes
WO2011112689A3 (en) Salts of an indazolylpyrrolotriazine
WO2013111013A3 (en) Methods for treating alzheimer's disease by administering certain synthetic compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11709838

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11709838

Country of ref document: EP

Kind code of ref document: A2